Arcturus Therapeutics Q4 2024: Discrepancies in Cystic Fibrosis Trials and Enrollment Expectations
Friday, Mar 7, 2025 6:37 am ET
1min read These are the key contradictions discussed in Arcturus Therapeutics' latest 2024Q4 earnings call, specifically including: CF Study Enrollment Progress and ARCT-032's Clinical Trial Plans, CF Trial Enrollment and Feasibility, CF Program Enrollment and Biomarker Expectations, and OTC Program Timeline and Targets:
Vaccine Program Milestones:
- Arcturus Therapeutics reported receiving European Commission approval for KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine.
- This approval is based on positive clinical data demonstrating KOSTAIVE's efficacy and safety against COVID-19 and higher immunogenicity results compared to conventional mRNA vaccines.
- The approval is valid in all 27 European Union member states and 3 additional European economic area countries.
Financial Performance and Revenue Trends:
- For the year ended December 31, 2024, Arcturus reported revenues of $152.3 million, a decrease of $14.5 million from the previous year.
- The decrease was primarily due to lower milestone achievements from the CSL agreement, offset by increased BARDA revenue due to pandemic flu program progress.
- For the quarter ended December 31, 2024, revenues were $22.8 million, a decrease of $8.1 million from the previous year, attributed to lower milestones from the CSL agreement.
Research and Development Expenses:
- Total research and development expenses for the year ended December 31, 2024, were $195.2 million, an increase from $192.1 million the previous year.
- The increase was primarily driven by higher clinical trial costs associated with OTC and CF programs and the COVID-19 and LUNAR-FLU programs in collaboration with CSL.
Interim Clinical Trial Data Expectations:
- Arcturus anticipates providing interim data from their CF participants who completed dosing in the ARCT-032 Phase II study by the end of Q2 2025.
- This data will likely include multiple subjects at multiple dose levels, with an FEV lung function improvement of 3% considered significant for advancing the program further.
Vaccine Program Milestones:
- Arcturus Therapeutics reported receiving European Commission approval for KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine.
- This approval is based on positive clinical data demonstrating KOSTAIVE's efficacy and safety against COVID-19 and higher immunogenicity results compared to conventional mRNA vaccines.
- The approval is valid in all 27 European Union member states and 3 additional European economic area countries.
Financial Performance and Revenue Trends:
- For the year ended December 31, 2024, Arcturus reported revenues of $152.3 million, a decrease of $14.5 million from the previous year.
- The decrease was primarily due to lower milestone achievements from the CSL agreement, offset by increased BARDA revenue due to pandemic flu program progress.
- For the quarter ended December 31, 2024, revenues were $22.8 million, a decrease of $8.1 million from the previous year, attributed to lower milestones from the CSL agreement.
Research and Development Expenses:
- Total research and development expenses for the year ended December 31, 2024, were $195.2 million, an increase from $192.1 million the previous year.
- The increase was primarily driven by higher clinical trial costs associated with OTC and CF programs and the COVID-19 and LUNAR-FLU programs in collaboration with CSL.
Interim Clinical Trial Data Expectations:
- Arcturus anticipates providing interim data from their CF participants who completed dosing in the ARCT-032 Phase II study by the end of Q2 2025.
- This data will likely include multiple subjects at multiple dose levels, with an FEV lung function improvement of 3% considered significant for advancing the program further.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.